TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling

Nature Communications

Volumn 5, Issue , 2014, Pages

  Ji, Hong ^a,b   Cao, Renhai ^a   Yang, Yunlong ^a   Zhang, Yin ^a   Iwamoto, Hideki ^a   Lim, Sharon ^a   Nakamura, Masaki ^a   Andersson, Patrik ^a   Wang, Jian ^a   Sun, Yuping ^c   Dissing, Steen ^d   He, Xia ^b   Yang, Xiaojuan ^a   Cao, Yihai ^a,e,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b JIANGSU CANCER HOSPITAL   (China)

^c JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e LINKÖPING UNIVERSITY   (Sweden)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3; SMALL INTERFERING RNA; VEGFR3 PROTEIN, HUMAN;

GENETIC VARIATION; GERM CELL; GROWTH RATE; SIGNALING; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE TARGETING; IN VIVO STUDY; LEUKOPENIA; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; CELL SEPARATION; CONFOCAL MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; MALE; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; TRANSGENIC MOUSE; U937 CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE DELETION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84923321580     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5944     Document Type: Article

References (55)

1. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361-371 (2009).
2. Johnstone, R. W., Frew, A. J. & Smyth, M. J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8, 782-798 (2008).
3. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810-816 (2000).
4. Varfolomeev, E. E. & Ashkenazi, A. Tumor necrosis factor: an apoptosis JuNKie? Cell 116, 491-497 (2004).
5. Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D. & Wallach, D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264, 11974-11980 (1989).
6. Engelmann, H., Novick, D. & Wallach, D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological crossreactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 265, 1531-1536 (1990).
7. Croft, M., Benedict, C. A. & Ware, C. F. Clinical targeting of the TNF and TNFR superfamilies. Nat. Rev. Drug Discov. 12, 147-168 (2013).
8. Faustman, D. & Davis, M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9, 482-493 (2010).
9. Karin, M. & Gallagher, E. TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol. Rev. 228, 225-240 (2009).
10. Ran, S. & Montgomery, K. E. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel) 4, 618-657 (2012).
11. Ji, R. C. Lymphatic endothelial cells, inflammatory lymphangiogenesis, and prospective players. Curr. Med. Chem. 14, 2359-2368 (2007).
12. Alitalo, K., Tammela, T. & Petrova, T. V. Lymphangiogenesis in development and human disease. Nature 438, 946-953 (2005).
13. Tammela, T. & Alitalo, K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 140, 460-476 (2010).
14. Baluk, P. et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J. Clin. Invest. 115, 247-257 (2005).
15. Guo, R. et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum. 60, 2666-2676 (2009).
16. Huggenberger, R. et al. An important role of lymphatic vessel activation in limiting acute inflammation. Blood 117, 4667-4678 (2011).
17. Huggenberger, R. et al. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J. Exp. Med. 207, 2255-2269 (2010).
18. Zhou, Q. et al. Vascular endothelial growth factor C attenuates joint damage in chronic inflammatory arthritis by accelerating local lymphatic drainage in mice. Arthritis Rheum. 63, 2318-2328 (2011).
19. Baluk, P. et al. TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. J. Clin. Invest. 119, 2954-2964 (2009).
20. Chaitanya, G. V. et al. Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro. Lymphat. Res. Biol. 8, 155-164 (2010).
21. Yan, Z. X., Jiang, Z. H. & Liu, N. F. Angiopoietin-2 promotes inflammatory lymphangiogenesis and its effect can be blocked by the specific inhibitor L1-10. Am. J. Physiol. Heart Circ. Physiol 302, H215-H223 (2012).
22. Cao, R. et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc. Natl Acad. Sci. USA 109, 15894-15899 (2012).
23. Papakonstanti, E. A. & Stournaras, C. Tumor necrosis factor-alpha promotes survival of opossum kidney cells via Cdc42-induced phospholipase C-gamma1 activation and actin filament redistribution. Mol. Biol. Cell 15, 1273-1286 (2004).
24. Joukov, V. et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16, 3898-3911 (1997).
25. Cao, R. et al. Mouse corneal lymphangiogenesis model. Nat. Protoc. 6, 817-826 (2011).
26. Cao, R. et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 107, 3531-3536 (2006).
27. Kleppe, M. et al. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol. Oncol. 123, 610-614 (2011).
28. Kulbe, H. et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 67, 585-592 (2007).
29. Nagy, J. A. et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196, 1497-1506 (2002).
30. Frater-Schroder, M., Risau, W., Hallmann, R., Gautschi, P. & Bohlen, P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl Acad. Sci. USA 84, 5277-5281 (1987).
31. Wan, T. et al. Functional analyses of TNFR2 in physiological and pathological retina angiogenesis. Invest. Ophthalmol. Vis. Sci. 54, 211-221 (2013).
32. Kubo, H. et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl Acad. Sci. USA 99, 8868-8873 (2002).
33. Cao, R. et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6, 333-345 (2004).
34. Nakao, S. et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J. Clin. Invest. 115, 2979-2991 (2005).
35. Achen, M. G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl Acad. Sci. USA 95, 548-553 (1998).
36. Jeon, B. H. et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 68, 1100-1109 (2008).
37. Balkwill, F. et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 2, 1229-1232 (1987).
38. Ristimaki, A., Narko, K., Enholm, B., Joukov, V. & Alitalo, K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem. 273, 8413-8418 (1998).
39. Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445-455 (2013).
40. Leibovich, S. J. et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329, 630-632 (1987).
41. Chuang, M. J. et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci. 99, 905-913 (2008).
42. Lockwood, C. J. et al. Matrix metalloproteinase 9 (MMP9) expression in preeclamptic decidua and MMP9 induction by tumor necrosis factor alpha and interleukin 1 beta in human first trimester decidual cells. Biol. Reprod. 78, 1064-1072 (2008).
43. Ardestani, S. et al. Membrane versus soluble isoforms of TNF-alpha exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res. 73, 3938-3950 (2013).
44. Bjorndahl, M. et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc. Natl Acad. Sci. USA 102, 15593-15598 (2005).
45. Gale, N. W. et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 3, 411-423 (2002).
46. Morisada, T. et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 105, 4649-4656 (2005).
47. Zhu, N. et al. Melanoma cell migration is upregulated by tumour necrosis factor-alpha and suppressed by alpha-melanocyte-stimulating hormone. Br. J. Cancer 90, 1457-1463 (2004).
48. Das, S. et al. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J. Exp. Med. 210, 1509-1528 (2013).
49. Yang, X. et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 110, 13932-13937 (2013).
50. Cao, R. H. et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 9, 604-613 (2003).
51. Hedlund, E. M. et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc. Natl Acad. Sci. USA 110, 654-659 (2013).
52. Yang, Y. et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc. Natl Acad. Sci. USA 110, 12018-12023 (2013).
53. Hosaka, K. et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nat. Commun. 4, 2129 (2013).
54. Xue, Y. et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat. Med. 18, 100-110 (2012).
55. Jensen, L. D. et al. Opposing effects of circadian clock genes bmal1 and period2 in regulation of VEGF-dependent angiogenesis in developing zebrafish. Cell Rep. 2, 231-241 (2012).